title: Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation.
abstract: We measured striatal dopamine transporter binding using [(123)I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2-PD) and in gene-negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2-PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 +/- 14 years, disease duration 9 +/- 3 years, and UPDRS III motor score 21.60 +/- 6.65. The control IPD group consisted of 15 patients with mean age 59 +/- 9 years, disease duration 9 +/- 5 years, and UPDRS III motor score 23.80 +/- 8.69. [(123)I]ioflupane-specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2-PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between-group values. We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD.
authors: Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy.
authors: Ioannis U
authors: IU
authors: Isaias
authors: Riccardo
authors: R
authors: Benti
authors: Stefano
authors: S
authors: Goldwurm
authors: Michela
authors: M
authors: Zini
authors: Roberto
authors: R
authors: Cilia
authors: Paolo
authors: P
authors: Gerundini
authors: Alessio
authors: A
authors: Di Fonzo
authors: Vincenzo
authors: V
authors: Bonifati
authors: Gianni
authors: G
authors: Pezzoli
authors: Angelo
authors: A
authors: Antonini